SXF VERIFIED BRIEF
A research collaboration organized thousands of GPT-Rosalind agents to study existing gene-perturbation measurements from millions of mouse brain cells in parallel. Each agent examined a perturbation, searched the literature and proposed an explanation; reports were merged into a publicly accessible reasoning atlas.
The result is a scalable way to prioritize laboratory follow-up, not a newly proven treatment. Reported leads include a cerebellar difference between Tsc1 and Tsc2 gene disruptions and a possible cholesterol-regulation connection to neurodegeneration. These are mechanistic research hypotheses to be experimentally tested.
The 32-minute run measures the computational interpretation of existing data, not collection of new experiments or clinical discovery. The >700-versus-11 citation comparison uses the authors' defined largest workload; more references alone do not establish correctness. Mouse cells and preprint-level evidence cannot establish human therapeutic benefit.